Basisstatistiken
| CIK | 793160 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Igene Biotechnology, Inc. - Preferred Security
SEC Filings (Chronological Order)
Auf dieser Seite finden Sie eine vollständige, chronologische Liste der SEC-Einreichungen, mit Ausnahme der Eigentumseinreichungen, die wir an anderer Stelle bereitstellen.
| April 10, 2017 |
IGNE / IGENE Biotechnology, Inc. / CANACCORD GENUITY INC. Passive Investment SC 13G/A 1 ignes13G.V2.txt UNITED STATES SECURITIES AND EXCHANGE COMMISSION "Washington, D.C. 20549" SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* IGENE BIOTECHNOLOGY INC (Name of Issuer) COMMON STOCK (Title of Class of Securities) 451695100 (CUSIP Number) 7-Apr-17 (Date of Event which Requires Filing of this Statement) Checktheappropriatebox to designate the rule pursua |
|
| April 7, 2017 |
IGNE / IGENE Biotechnology, Inc. / CANACCORD GENUITY INC. Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION "Washington, D.C. 20549" SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* IGENE BIOTECHNOLOGY INC (Name of Issuer) COMMON STOCK (Title of Class of Securities) 451695100 (CUSIP Number) 7-Apr-17 (Date of Event which Requires Filing of this Statement) Checktheappropriatebox to designate the rule pursuant to which this Schedule i |
|
| January 10, 2017 |
IGNE / IGENE Biotechnology, Inc. / CANACCORD GENUITY INC. Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* IGENE BIOTECHNOLOGY INC (Name of Issuer) COMMON STOCK (Title of Class of Securities) 451695100 (CUSIP Number) DECEMBER 30, 2016 (Date of Event which Requires Filing of this Statement) Checktheappropriatebox to designate the rule pursuant to which this Sch |
|
| March 15, 2011 |
FORM 15 - NOTICE OF TERMINATION OF REGISTRATION OF A CLASS OF SECURITIES UNDER SECTION 12(G) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 0-15888 IGENE BIOTECHNOLOGY, INC. (Exact name of registrant as specified in |
|
| November 15, 2010 |
QUARTERLY FILING FOR PERIOD ENDED SEPTEMBER 30 2010 - DOES NOT INCLUDE EXHIBITS 10-Q 1 q09302010.txt QUARTERLY FILING FOR PERIOD ENDED SEPTEMBER 30 2010 - DOES NOT INCLUDE EXHIBITS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OFTHE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2010 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d)OF THE EXCHA |
|
| August 13, 2010 |
10Q FOR PERIOD ENDED JUNE 30 2010 - MAIN TEXT OF FILING 10-Q 1 q06302010.txt 10Q FOR PERIOD ENDED JUNE 30 2010 - MAIN TEXT OF FILING UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) [x] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2010 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE EXCHANGE ACT For the transition |
|
| May 14, 2010 |
QUARTERLY REPORT FOR PERIOD ENDED MARCH 31 2010 W/O EXHIBITS U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2010 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE EXCHANGE ACT For the transition period from to Commission file number 0-15888 IGENE Biotechnology, Inc. (Exact name of registran |
|
| March 31, 2010 |
EX-21 2 filing10k2009ex211.txt SUBSIDIARIES OF IGENE BIOTECHNOLOGY INC. EXHIBIT 21.1 SUBSIDIARIES OF IGENE BIOTECHNOLOGY, INC. The table below sets forth all subsidiaries of Igene Biotechnology, Inc. and the state or other jurisdiction of incorporation or organization of each. Subsidiary Jurisdiction of Organization Igene Chile Comercial, Ltda. Chile |
|
| March 31, 2010 |
10K FILING FOR PERIOD ENDED DECEMBER 31 2009 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) [x] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2009 or [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 0-15888 IGENE Biotech |
|
| December 1, 2009 |
Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report: November 24, 2009 (Date of earliest event reported) IGENE BIOTECHNOLOGY, INC. |
|
| November 24, 2009 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14C INFORMATION Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 Check the appropriate box: [ ] Preliminary Information Statement [ ] Confidential, for Use of the Commission Only (as permitted by Rule 14c-5(d)(2)) [X] Definitive Information Statement IGENE BIOTECHNOLOGY, INC. (Nam |
|
| November 13, 2009 |
QUARTERLY FILING FOR PERIOD ENDED SEPTEMBER 30 2009 - BODY UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) [x] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2009 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE EXCHANGE ACT For the transition period from to Commission file number 000-15888 IGENE Biotechnology, Inc |
|
| November 13, 2009 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14C INFORMATION Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 Check the appropriate box: [X] Preliminary Information Statement [ ] Confidential, for Use of the Commission Only (as permitted by Rule 14c-5(d)(2)) [ ] Definitive Information Statement IGENE BIOTECHNOLOGY, INC. (Nam |
|
| August 14, 2009 |
QUARTERLY REPORT FOR PERIOD ENDED JUNE 30 2009 W/O EXHIBITS 10-Q 1 q06302009.txt QUARTERLY REPORT FOR PERIOD ENDED JUNE 30 2009 W/O EXHIBITS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2009 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE EXCHANGE ACT For the transit |
|
| May 15, 2009 |
BODY OF FILING FIRST QUARTER ENDED MARCH 31 2009 U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) [x] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2009 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE EXCHANGE ACT For the transition period from to Commission file number 0-15888 IGENE Biotechnology, Inc. (Exact name o |
|
| April 1, 2009 |
EXHIBIT 21.1 SUBSIDIARIES OF IGENE BIOTECHNOLOGY, INC. The table below sets forth all subsidiaries of Igene Biotechnology, Inc. and the state or other jurisdiction of incorporation or organization of each. Subsidiary Jurisdiction of Organization Igene Chile Comercial, Ltda. Chile |
|
| April 1, 2009 |
10 K FOR YEAR ENDED DECEMBER 31 2008 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2008 or [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 0-15888 IGENE Biotech |
|
| April 1, 2009 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check one): [x] Form 10-K [ ] Form 20-F [ ] Form 11-K [ ] Form 10-Q [ ] Form 10-D [ ] Form N-SAR [ ] Form N-CSR For Period Ended: December 31, 2008 [ ] Transition report on Form 10-K [ ] Transition Report on Form 20-F [ ] Transition Report on Form 11-K [ ] Transition Report on Form 10-Q |
|
| March 24, 2009 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION March 20, 2009 ORDER GRANTING CONFIDENTIAL TREATMENT UNDER THE SECURITIES EXCHANGE ACT OF 1934 Igene Biotechnology, Inc. |
|
| February 27, 2009 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b)(c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. |
|
| January 21, 2009 |
LIMITED LIABILITY COMPANY AGREEMENT NATURXAN LLC INFORMATION FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED PURSUANT TO RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED, IS OMITTED AND IS NOTED WITH ****. |
|
| January 21, 2009 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) Of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported):January 8, 2009 IGENE BIOTECHNOLOGY, INC. |
|
| January 12, 2009 |
OMB APPROVAL OMB Number: 3235-0145 Expires: February 28, 2009 Estimated average burden hours per response. |
|
| January 12, 2009 |
Exhibit 1 JOINT FILING AGREEMENT In accordance with Rule 13d-1 (f) under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree to the joint filing with all other Reporting Entities (as such term is defined in the Schedule 13G) on behalf of each of them of a statement on Schedule 13G (including amendments thereto) with respect to the Common Stock, $0. |
|
| January 8, 2009 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934* (Amendment No. 7) IGENE Biotechnology, Inc. (Name of Issuer) Common Stock, $0.01 Par Value (Title of Class of Securities) 451695 10 0 (CUSIP Number) Martin H. Neidell Stroock & Stroock & Lavan LLP 180 Maiden Lane New York, New York 10038 (212) 806-5836 (Name, Address and Telephone Nu |
|
| November 3, 2008 |
10Q FILING W/O EXHIBITS FOR PERIOD ENDED SEPTEMBER 30 2008 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) [ x ] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2008 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE EXCHANGE ACT For the transition period from to Commission file number 000-15888 IGENE Biotechnology, I |
|
| October 3, 2008 |
CORRESP 1 filename1.txt IGENE BIOTECHNOLOGY, INC. 9110 Red Branch Road Columbia, MD 21045-2024 Phone: (+1) 410-997-2599 Fax: (+1) 410-730-0540 www.igene.com October 2, 2008 VIA EDGAR, FACSIMILE AND FEDEX Max A. Webb U.S. Securities and Exchange Commission Division of Corporation Finance 100 F. Street, N.E. Washington, D.C. 20549 IGENE Biotechnology, Inc. Proxy Statement on Schedule 14A Filed Octob |
|
| October 3, 2008 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement Under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 IGENE BIOTECHNOLOGY, INC. (Name of Subject Company (Issuer)) IGENE BIOTECHNOLOGY, INC. (Names of Filing Persons (Issuer and Offeror) Warrants to Purchase Common Stock, $.01 Par Value Per Share (Title of Class of Securities) 451695100 |
|
| October 3, 2008 |
SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant [X] Filed by a Party other than the Registrant [ ] Check the appropriate box: [ ] Preliminary Proxy Statement [ ] Confidential, for use of the Commission only (as [ ] permitted by Rule 14a-6(e)(2)) [X] Definitive Proxy Statement [ ] Definitive Additional Materials [ ] Soliciting Material Under Rule 14a-12 IGENE Biotechnology, Inc. |
|
| September 24, 2008 |
WRITTEN COMMUNICATION RELATING TO ISSUER TENDER OFFER SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement Under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 IGENE BIOTECHNOLOGY, INC. (Name of Subject Company (Issuer)) IGENE BIOTECHNOLOGY, INC. (Names of Filing Persons (Issuer and Offeror) Warrants to Purchase Common Stock, $.01 Par Value Per Share (Title of Class of Securities) 451695100 |
|
| September 24, 2008 |
PRER14A 1 prelimproxy2008a.txt SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Amendment No. 1 Filed by the Registrant [X] Filed by a Party other than the Registrant [ ] Check the appropriate box: [X] Preliminary Proxy Statement [ ] Confidential, for use of the Commission only (as [ ] permitted by Rule 14a-6(e)(2)) [ ] Definitive Proxy Stat |
|
| September 24, 2008 |
CORRESP 1 filename1.txt IGENE BIOTECHNOLOGY, INC. 9110 Red Branch Road Columbia, MD 21045-2024 Phone: (+1) 410-997-2599 Fax: (+1) 410-730-0540 www.igene.com September 24, 2008 VIA EDGAR, FACSIMILE AND FEDEX Max A. Webb U.S. Securities and Exchange Commission Division of Corporation Finance 100 F. Street, N.E. Washington, D.C. 20549 IGENE Biotechnology, Inc. Amendment No. 1 to Preliminary Proxy Sta |
|
| September 18, 2008 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 DIVISION OF CORPORATION FINANCE Mail Stop 3561 September 18, 2008 Via Facsimile (410) 730-0540 and U.S. Mail Edward J. Weisberger Chief Financial Officer IGENE Biotechnology, Inc. 9110 Red Branch Road Columbia, MD 21045 Re: IGENE Biotechnology, Inc. Preliminary Schedule 14A Filed September 12, 2008 File No. 000-15888 Dear Mr. |
|
| September 12, 2008 |
PRELIMINARY PROXY STATEMENT 2008 PRE 14A 1 proxy2008.txt PRELIMINARY PROXY STATEMENT 2008 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant [X] Filed by a Party other than the Registrant [ ] Check the appropriate box: [X] Preliminary Proxy Statement [ ] Confidential, for use of the Commission only (as [ ] permitted by Rule 14a-6(e)(2)) [ ] Definitive |
|
| August 7, 2008 |
10Q FOR PERIOD ENDED JUNE 30 2008 W/O EXHIBITS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) [x] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2008 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE EXCHANGE ACT For the transition period from to Commission file number 0-15888 IGENE Biotechnology, Inc. (Exac |
|
| May 15, 2008 |
10Q FILING FOR PERIOD ENDED MARCH 31 2008 W/O EXHIBITS U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2008 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE THE EXCHANGE ACT For the transition period from to Commission file number 0-15888 IGENE Biotechnology, Inc. (Exact na |
|
| May 6, 2008 |
10KSB FILING TEXT FILING W/O EXHIBITS SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-KSB (Mark One) [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the fiscal year ended December 31, 2007 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 0-15888 IGENE Biotechnology, Inc. ( |
|
| May 6, 2008 |
EXHIBIT 21.1 SUBSIDIARIES OF IGENE BIOTECHNOLOGY, INC. The table below sets forth all subsidiaries of Igene Biotechnology, Inc. and the state or other jurisdiction of incorporation or organization of each. Subsidiary Jurisdiction of Organization Igene Chile Comercial, Ltda. Chile |
|
| March 31, 2008 |
NOTICE UNDER RULE 12B25 OF INABILITY TO TIMELY FILE ALL OR PART OF FORM 10-KSB SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 Notification of Late Filing Commission File Number: 0-15888 (Check one) [x] Form 10-K or 10-KSB [ ] Form 20-F [ ] Form 11-K [ ] Form 10-Q or 10-QSB [ ] Form 10-D [ ] Form N-SAR [ ] Form N-CSR For period ended December 31, 2007 [ ] Transition Report on Form 10-K [ ] Transition Report on Form 20-F [ ] Transition Report on Form 11- |
|
| March 11, 2008 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934* (Amendment No. 6) IGENE Biotechnology, Inc. (Name of Issuer) Common Stock, $0.01 Par Value (Title of Class of Securities) 451695 10 0 (CUSIP Number) Martin Neidell, Esq. Stroock & Stroock & Lavan LLP 180 Maiden Lane New York, New York 10038 (212) 806-5400 (Name, Address and Telephone |
|
| February 7, 2008 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 28, 2008 IGENE BIOTECHNOLOGY, INC. (Exact Name of Registrant as Specified in its Charter) Maryland (State or Other Jurisdiction of Incorporation or Organization) 0-15888 52-1230461 (Commiss |
|
| January 28, 2008 |
January 28, 2008 Zip+4 Code: 20549-0305 Via Fax & U.S. Mail Mr. Stephen F. Hiu President Igene Biotechnology, Inc. 9110 Red Brach Road Columbia, MD 21045-2024 Re: Form 8-K filed January 22, 2008 File No.: 0-15888 Dear Mr. Hiu: We have reviewed your filing and have the following comments. Where indicated, we think you should revise your document in response to these comments. Please understand that |
|
| January 22, 2008 |
5 Exhibit 16 January 22, 2008 Securities and Exchange Commission 100 F Street, N.E. Washington, DC 20549 Ladies and Gentlemen: We have read Item 4.01 of Form 8-K of Igene Biotechnology, Inc., to be filed with the Securities and Exchange Commission on January 22, 2008, and are in agreement with the statements contained under Item 4.01(a) therein. We have no basis to agree or disagree with the state |
|
| January 22, 2008 |
FORM 8-K SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 11, 2008 IGENE BIOTECHNOLOGY, INC. (Exact name of registrant as specified in its charter) MARYLAND 0-15888 52-1230461 (State or other jurisdiction (Commission (IRS Employer of incorporation |
|
| December 21, 2007 |
BODY W/O EXHIBITS OF RESTATED 10QSB/A FOR PERIOD ENDED 03-31-2007 10QSB/A 1 qsba03312007bodyrestated.txt BODY W/O EXHIBITS OF RESTATED 10QSB/A FOR PERIOD ENDED 03-31-2007 U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-QSB/A (Amendment #1) (Mark One) [x] Quarterly report under Section 13 or 15(D) of the Securities Exchange Act of 1934 For the quarterly period ended March 31, 2007 [ ] Transition report under Section 13 or 15(D) of the Excha |
|
| December 21, 2007 |
FILING W/O EXHIBITS OF 10QSB FOR PERIOD ENDED 06-30-2007 U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-QSB (Mark One) [x] Quarterly report under Section 13 or 15(D) of the Securities Exchange Act of 1934 For the quarterly period ended June 30, 2007 [ ] Transition report under Section 13 or 15(D) of the Exchange Act For the transition period from to Commission file number 0-15888 IGENE Biotechnology, Inc. (Exact name of Small Bus |
|
| December 21, 2007 |
BODY W/O EXHIBITS FOR RESTATED 2006 10KSB/A 10KSB/A 1 restated200610ksbabody.txt BODY W/O EXHIBITS FOR RESTATED 2006 10KSB/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-KSB/A (Amendment #1) (Mark One) [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the fiscal year ended December 31, 2006 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF |
|
| December 21, 2007 |
FILING OF 10QSB W/O EXHIBITS FOR PERIOD ENDED 09-30-2007 U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-QSB (Mark One) [x] Quarterly report under Section 13 or 15(D) of the Securities Exchange Act of 1934 For the quarterly period ended September 30, 2007 [ ] Transition report under Section 13 or 15(D) of the Exchange Act For the transition period from to Commission file number 0-15888 IGENE Biotechnology, Inc. (Exact name of Smal |
|
| November 15, 2007 |
FORM 12B-25 NOTIFICATION OF LATE FILING UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING Commission File Number: 000-25349 (Check One): [ ] Form 10-KSB [ ] Form 20-F [ ] Form 11-K [x] Form 10-QSB [ ] Form N-SAR [ ] Form N-CSR For Period Ended: September 30, 2007 [ ] Transition Report on Form 10-K and Form 10-KSB [ ] Transition Report on Form 20-F [ ] Transition Report on For |
|
| November 6, 2007 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) Of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 31, 2007 IGENE BIOTECHNOLOGY, INC. |
|
| November 6, 2007 |
SEPARATION AGREEMENT This Separation Agreement (this "Agreement") is made and entered into as of the 31st day of October, 2007 by and between Igene Biotechnology, Inc. |
|
| August 15, 2007 |
TEXT DOCUMENT OF NT-10Q; INABILITY TO TIMELY FILE PERIOD 06-30-2007 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING Commission File Number: 000-15888 (Check One): [ ] Form 10-KSB [ ] Form 20-F [ ] Form 11-K [X] Form 10-QSB [ ] Form N-SAR [ ] Form N-CSR For Period Ended: June 30, 2007 [ ] Transition Report on Form 10-K and Form 10-KSB [ ] Transition Report on Form 20-F [ ] Transition Report on Form 11- |
|
| May 15, 2007 |
10QSB FOR PERIOD ENDED MARCH 31, 2007 - W/O EXHIBITS 10QSB 1 qsb03312007.txt 10QSB FOR PERIOD ENDED MARCH 31, 2007 - W/O EXHIBITS U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-QSB (Mark One) [x] Quarterly report under Section 13 or 15(D) of the Securities Exchange Act of 1934 For the quarterly period ended March 31, 2007 [ ] Transition report under Section 13 or 15(D) of the Exchange Act For the transition period from to Com |
|
| May 10, 2007 |
8-K REPORT CHANGES IN ACCOUNTANTS SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 9, 2007 IGENE BIOTECHNOLOGY, INC. (Exact name of registrant as specified in its charter) MARYLAND 0-15888 52-1230461 (State or other (Commission File (IRS Employer jurisdiction Number) Identifi |
|
| May 10, 2007 |
EX-16.1 May 3, 2007 Securities and Exchange Commission 100 F Street, N.W. Washington, DC 20549 Ladies and Gentlemen: We have reviewed the disclosures made by Igene Biotechnology, Inc. and Subsidiaries (the "Company") in its current report on Form 8-K which is to be filed with the Securities and Exchange Commission ("SEC"). Pursuant to Item 304(a)(3) of Regulation S-K, we are required to furnish th |
|
| March 30, 2007 |
10KSB FOR PERIOD ENDED DECEMBER 31 2006 - MAIN TEXT W/O EXHIBITS SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-KSB (Mark One) [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the fiscal year ended December 31, 2006 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 0-15888 IGENE Biotechnology, Inc. ( |
|
| November 13, 2006 |
10QSB FOR PERIOD ENDED SEPTEMBER 30, 2006 - MAIN TEXT U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-QSB (Mark One) [x] Quarterly report under Section 13 or 15(D) of the Securities Exchange Act of 1934 For the quarterly period ended September 30, 2006 [ ] Transition report under Section 13 or 15(D) of the Exchange Act For the transition period from to Commission file number 0-15888 IGENE Biotechnology, Inc. (Exact name of Smal |
|
| August 11, 2006 |
10-QSB FILING FOR PERIOD ENDED JUNE 30, 2006 - MAIN BODY OF TEXT W/O EXHIBITS 10QSB 1 qsb06302006.txt 10-QSB FILING FOR PERIOD ENDED JUNE 30, 2006 - MAIN BODY OF TEXT W/O EXHIBITS U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-QSB (Mark One) [x] Quarterly report under Section 13 or 15(D) of the Securities Exchange Act of 1934 For the quarterly period ended June 30, 2006 [ ] Transition report under Section 13 or 15(D) of the Exchange Act For the trans |
|
| June 2, 2006 |
DEFINITIVE PROXY STATEMENT PURSUANT TO SECTION 14(A) OF THE SECURITIES EXCHANGE ACT OF 1934 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant [X] Filed by a Party other than the Registrant [ ] Check the appropriate box: [ ] Preliminary Proxy Statement [ ] Confidential, for use of the Commission only (as permitted by Rule 14a-6(e)(2)) [X] Definitive Proxy Statement [ ] Definitive Additional Materials [ ] Soliciting Material Under Rule 14a-12 IGENE Biotechnology, Inc. |
|
| May 19, 2006 |
QUARTERLY REPORT FOR PERIOD ENDED MARCH 31, 2006 U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-QSB (Mark One) [x] Quarterly report under Section 13 or 15(D) of the Securities Exchange Act of 1934 For the quarterly period ended March 31, 2006 [ ] Transition report under Section 13 or 15(D) of the Exchange Act For the transition period from to Commission file number 0-15888 IGENE Biotechnology, Inc. (Exact name of Small Bu |
|
| May 15, 2006 |
FORM 12B-25 - NOTIFICATION OF LATE FILING - BODY NT 10-Q 1 form12b2503312006body.txt FORM 12B-25 - NOTIFICATION OF LATE FILING - BODY UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING Commission File Number: 000-15888 (Check One): [ ] Form 10-KSB [ ] Form 20-F [ ] Form 11-K [X] Form 10-QSB [ ] Form N-SAR [ ] Form N-CSR For Period Ended: March 31, 2006 [ ] Transition Report on Form 10- |
|
| May 15, 2006 |
Exhibit 99 Auditor's Statement Igene Biotechnology, Inc. 9110 Red Branch Road Columbia, Maryland 21045 Gentlemen: In connection with the filing of the Form 10-QSB for the fiscal quarter ended March 31, 2006, please be advised that we are unable to complete our review of the financial statements by the due date of May 15, 2006. We are awaiting information necessary to complete the review from Igene |
|
| April 13, 2006 |
EXHIBIT 23.a. CONSENT OF INDEPENDENT AUDITORS We hereby consent to the incorporation by reference in the Registration Statements Nos. 333-76616, 333-65013 and 333-6103 each on Form S-8 and to Registration Statement No. 333-45218 on Form S-3, and in the Annual Report on Form 10-KSB of Igene Biotechnology, Inc. for the years ended December 31, 2005 and 2004 of our report dated March 9, 2006, relatin |
|
| April 13, 2006 |
EXHIBIT 10.11 The Royal Bank of Scotland plc Limited Guarantee by one Company of another Secs 28 International (7/95) THIS IS AN IMPORTANT DOCUMENT. YOU SHOULD TAKE INDEPENDENT LEGAL ADVICE BEFORE SIGNING AND SIGN ONLY IF YOU WANT TO BE LEGALLY BOUND. IF YOU SIGN AND THE BANK IS NOT PAID YOU MAY HAVE TO PAY INSTEAD OF THE DEBTOR. YOUR LIABILITY UNDER THIS DOCUMENT IS LIMITED AS PROVIDED IN CLAUSE |
|
| April 13, 2006 |
EXHIBIT 4.5 SECOND AMENDMENT TO INDENTURE, SECURITIES, WARRANT AGREEMENT AND WARRANT CERTIFICATES THIS SECOND AMENDMENT TO INDENTURE, SECURITIES, WARRANT AGREEMENT AND WARRANT CERTIFICATES (this "Second Amendment") is made as of and shall be effective for all purposes as of the 28th day of March, 2006, by and between Igene Biotechnology, Inc., a Maryland corporation (the "Company"), and American S |
|
| April 13, 2006 |
10KSB FOR PERIOD ENDED DECEMBER 31, 2005 BODY TEXT WITHOUT EXHIBITS SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-KSB (Mark One) [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the fiscal year ended December 31, 2005 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 0-15888 IGENE Biotechnology, Inc. ( |
|
| April 3, 2006 |
BODY OF FORM 12B-25 FILING PERTAINING TO PERIOD 12-31-2005 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING Commission File Number: 000-15888 (Check One): [x] Form 10-KSB [ ] Form 20-F [ ] Form 11-K [ ] Form 10-QSB [ ] Form N-SAR [ ] Form N-CSR For Period Ended: December 31, 2005 [ ] Transition Report on Form 10-K and Form 10-KSB [ ] Transition Report on Form 20-F [ ] Transition Report on Form |
|
| April 3, 2006 |
Exhibit 99 Auditor's Statement Igene Biotechnology, Inc. 9110 Red Branch Road Columbia, Maryland 21045 Gentlemen: In connection with the filing of the Form 10-KSB for the fiscal year ended December 31, 2005, please be advised that we are unable to render our opinion on the financial statements by the due date of March 31, 2006. We are awaiting information necessary to complete the audit from Igene |
|
| March 31, 2006 |
Exhibit 4 SECOND AMENDMENT TO INDENTURE, SECURITIES, WARRANT AGREEMENT AND WARRANT CERTIFICATES THIS SECOND AMENDMENT TO INDENTURE, SECURITIES, WARRANT AGREEMENT AND WARRANT CERTIFICATES (this "Second Amendment") is made as of and shall be effective for all purposes as of the 28th day of March, 2006, by and between Igene Biotechnology, Inc. |
|
| March 31, 2006 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 28, 2006 IGENE BIOTECHNOLOGY, INC. (Exact Name of registrant as specified in its charter) Maryland 01-15888 52-1230461 (State or other (Commission File (IRS Employer jurisdiction of Number) I |
|
| March 15, 2006 |
MARCH 30, 2005 QSB FILING MAIN TEXT 10QSB 1 qsb032005.txt MARCH 30, 2005 QSB FILING MAIN TEXT U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-QSB (Mark One) [x] Quarterly report under Section 13 or 15(D) of the Securities Exchange Act of 1934 For the quarterly period ended March 31, 2005 [ ] Transition report under Section 13 or 15(D) of the Exchange Act For the transition period from to Commission file number |
|
| March 15, 2006 |
SEPTEMBER 30, 2005 QSB MAIN TEXT ONLY U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-QSB (Mark One) [x] Quarterly report under Section 13 or 15(D) of the Securities Exchange Act of 1934 For the quarterly period ended September 30, 2005 [ ] Transition report under Section 13 or 15(D) of the Exchange Act For the transition period from to Commission file number 0-15888 IGENE Biotechnology, Inc. (Exact name of Smal |
|
| March 15, 2006 |
10QSB 1 qsb062005.txt JUNE 30, 2005 QSB MAIN TEXT U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-QSB (Mark One) [x] Quarterly report under Section 13 or 15(D) of the Securities Exchange Act of 1934 For the quarterly period ended June 30, 2005 [ ] Transition report under Section 13 or 15(D) of the Exchange Act For the transition period from to Commission file number 0-15888 |
|
| November 16, 2005 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING Commission File Number: 000-15888 (Check One): [ ] Form 10-KSB [ ] Form 20-F [ ] Form 11-K [X] Form 10-QSB [ ] Form N-SAR [ ] Form N-CSR For Period Ended: September 30, 2005 [ ] Transition Report on Form 10-K and Form 10-KSB [ ] Transition Report on Form 20-F [ ] Transition Report on For |
|
| October 12, 2005 |
DEFINITIVE PROXY STATEMENT - EDGAR FORMAT DEF 14A 1 proxy2005.txt DEFINITIVE PROXY STATEMENT - EDGAR FORMAT SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant [X] Filed by a Party other than the Registrant [ ] Check the appropriate box: [ ] Preliminary Proxy Statement [ ] Confidential, for use |
|
| October 6, 2005 |
10KSB FOR PERIOD ENDED DECEMBER 31 2004 TEXT W/O EXHIBITS SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-KSB (Mark One) [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the fiscal year ended December 31, 2004 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 0-15888 IGENE Biotechnology, Inc. ( |
|
| September 30, 2005 |
10QSB/A FOR PERIOD ENDED MARCH 31, 2004 WITHOUT EXHIBITS U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-QSB/A (Amendment #1) (Mark One) [x] Quarterly report under Section 13 or 15(D) of the Securities Exchange Act of 1934 For the quarterly period ended March 31, 2004 [ ] Transition report under Section 13 or 15(D) of the Exchange Act For the transition period from to Commission file number 0-15888 IGENE Biotechnology, Inc. (Exact |
|
| September 30, 2005 |
QSB/A FOR PERIOD ENDED JUNE 30 2004 W/O EXHIBITS U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-QSB/A (Amendment No. 1) (Mark One) [x] Quarterly report under Section 13 or 15(D) of the Securities Exchange Act of 1934 For the quarterly period ended June 30, 2004 [ ] Transition report under Section 13 or 15(D) of the Exchange Act For the transition period from to Commission file number 0-15888 IGENE Biotechnology, Inc. (Exa |
|
| September 30, 2005 |
QSBA FOR PERIOD ENDED SEPTEMBER 30 2004 W/O EXHIBITS U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-QSB/A (Amendment No. 1) (Mark One) [x] Quarterly report under Section 13 or 15(D) of the Securities Exchange Act of 1934 For the quarterly period ended September 30, 2004 [ ] Transition report under Section 13 or 15(D) of the Exchange Act For the transition period from to Commission file number 0-15888 IGENE Biotechnology, Inc. |
|
| September 6, 2005 |
10KSB/A FOR PERIOD ENDED DECEMBER 31, 2003 W/O EXHIBITS SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-KSB/A (Amendment #1) (Mark One) [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the fiscal year ended December 31, 2003 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 0-15888 IGENE Biot |
|
| August 15, 2005 |
FORM 12B-25 NOTIFICATION OF LATE FILING FOR PERIOD ENDED JUNE 30 2005 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING Commission File Number: 000-15888 (Check One): [ ] Form 10-KSB [ ] Form 20-F [ ] Form 11-K [X] Form 10-QSB [ ] Form N-SAR [ ] Form N-CSR For Period Ended: June 30, 2005 [ ] Transition Report on Form 10-K and Form 10-KSB [ ] Transition Report on Form 20-F [ ] Transition Report on Form 11- |
|
| July 28, 2005 |
FULL TEXT OF QSB/A FOR PERIOD ENDED JUNE 30, 2003 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 10549 FORM 10-QSB/A (Amendment No.1) (Mark One) [x] Quarterly report under Section 13 or 15(D) of the Securities Exchange Act of 1934 For the quarterly period ended June 30, 2003 [ ] Transition report under Section 13 or 15(D) of the Exchange Act For the transition period from to Commission file number 0-15888 IGENE Biotechnology, Inc. (Exact nam |
|
| July 28, 2005 |
FULL TEXT VERSION OF QSB/A FOR PERIOD ENDED SEPTEMBER 30, 2003 10QSB/A 1 qsba09302003.txt FULL TEXT VERSION OF QSB/A FOR PERIOD ENDED SEPTEMBER 30, 2003 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 10549 FORM 10-QSB/A (Amendment No.1) (Mark One) [x] Quarterly report under Section 13 or 15(D) of the Securities Exchange Act of 1934 For the quarterly period ended September 30, 2003 [ ] Transition report under Section 13 or 15(D) of the Exchange Act For th |
|
| May 25, 2005 |
8-K/A 1 filing8ka05252005.txt AMENDMENT TO 8-K SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 8-K/A CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 12, 2005 IGENE BIOTECHNOLOGY, INC. (Exact Name of Registrant as Specified in its Charter) Maryland (State or Other Jurisdiction of Incorporation |
|
| May 25, 2005 |
Exhibit 99 LETTER OF AGREEMENT FROM BERENSON LLP May 13, 2005 Securities and Exchange Commission Mail Stop 11-3 450 5th Street, N. |
|
| May 17, 2005 |
DIVISION LETTERHEAD UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| May 16, 2005 |
Exhibit 99 LETTER OF AGREEMENT FROM BERENSON LLP May 13, 2005 Securities and Exchange Commission Mail Stop 11-3 450 5th Street, N. |
|
| May 16, 2005 |
NOTICE UNDER RULE 12B25 OF INABILITY TO TIMELY FILE ALL OR PART OF A FORM 10-Q OR 10-QSB NT 10-Q 1 form12b2503312005.txt NOTICE UNDER RULE 12B25 OF INABILITY TO TIMELY FILE ALL OR PART OF A FORM 10-Q OR 10-QSB UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING Commission File Number: 000-15888 (Check One): [ ] Form 10-KSB [ ] Form 20-F [ ] Form 11-K [X] Form 10-QSB [ ] Form N-SAR [ ] Form N-CSR For Period Ended: March 31, 20 |
|
| May 16, 2005 |
8-K 1 filing8k05162005.txt 8-K FILING OF MAY 16 2005 SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 12, 2005 IGENE BIOTECHNOLOGY, INC. (Exact Name of Registrant as Specified in its Charter) Maryland (State or Other Jurisdiction of Incorpora |
|
| April 1, 2005 |
NOTIFICATION OF LATE FILING OF FORM 10-KSB FOR PERIOD ENDED DECEMBER 31, 2004 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING Commission File Number: 000-25349 (Check One): [X] Form 10-KSB [ ] Form 20-F [ ] Form 11-K [ ] Form 10-QSB [ ] Form N-SAR [ ] Form N-CSR For Period Ended: December 31, 2004 [ ] Transition Report on Form 10-K and Form 10-KSB [ ] Transition Report on Form 20-F [ ] Transition Report on Form |
|
| February 17, 2005 |
EX-16 Letter of Agreement from Stegman & Company February 16, 2005 Securities and Exchange Commission Mail Stop 11-3 450 5th Street, N. |
|
| February 17, 2005 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 CURRENT REPORT FORM 8-K Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 16, 2005 IGENE BIOTECHNOLOGY, INC. (Exact name of registrant as specified in its charter) MARYLAND 0-15888 52-1230461 (State or other (Commission (IRS Employer jurisdiction o |
|
| November 12, 2004 |
QSB REPORT FOR PERIOD ENDED SEPTEMBER 30 2004 10QSB 1 qsb09302004mainbody.txt QSB REPORT FOR PERIOD ENDED SEPTEMBER 30 2004 U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-QSB (Mark One) [x] Quarterly report under Section 13 or 15(D) of the Securities Exchange Act of 1934 For the quarterly period ended September 30, 2004 [ ] Transition report under Section 13 or 15(D) of the Exchange Act For the transition period from t |
|
| August 13, 2004 |
MAIN BODY OF 10QSB FOR PERIOD ENDED JUNE 30 2004 U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-QSB (Mark One) [x] Quarterly report under Section 13 or 15(D) of the Securities Exchange Act of 1934 For the quarterly period ended June 30, 2004 [ ] Transition report under Section 13 or 15(D) of the Exchange Act For the transition period from to Commission file number 0-15888 IGENE Biotechnology, Inc. (Exact name of Small Bus |
|
| May 14, 2004 |
MAIN TEXT OF 10QSB FOR PERIOD ENDED MARCH 31 2004 U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-QSB (Mark One) [x] Quarterly report under Section 13 or 15(D) of the Securities Exchange Act of 1934 For the quarterly period ended March 31, 2004 [ ] Transition report under Section 13 or 15(D) of the Exchange Act For the transition period from to Commission file number 0-15888 IGENE Biotechnology, Inc. (Exact name of Small Bu |
|
| April 21, 2004 |
DEF 14A 1 proxy2004.txt DEFINITIVE PROXY STATEMENT SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant X Filed by a Party other than the Registrant Check the appropriate box: Preliminary Proxy Statement Confidential, for use of the Commission only (as pe |
|
| March 30, 2004 |
BODY OF 10KSB FILING FOR PERIOD ENDED 12 31 2003 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-KSB (Mark One) [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the fiscal year ended December 31, 2003 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 0-15888 IGENE Biotechnology, Inc. ( |
|
| March 30, 2004 |
EXHIBIT 23.a. CONSENT OF INDEPENDENT AUDITORS We hereby consent to the incorporation by reference in the Registration Statements Nos. 333-76616, 333-65013 and 333-6103 each on Form S-8 and to Registration Statement No. 333-45218 on Form S-3, and in the Annual Report on Form 10-KSB of Igene Biotechnology, Inc. for the year ended December 31, 2003 of our report dated March 25, 2004, relating to the |
|
| November 14, 2003 |
10QSB FILE FOR PERIOD ENDING SEPTEMBER 30, 2003 - MAIN TEXT SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 10549 FORM 10-QSB (Mark One) [x] Quarterly report under Section 13 or 15(D) of the Securities Exchange Act of 1934 For the quarterly period ended September 30, 2003 [ ] Transition report under Section 13 or 15(D) of the Exchange Act For the transition period from to Commission file number 0-15888 IGENE Biotechnology, Inc. (Exact name of Small Bus |
|
| October 1, 2003 |
FORM 8-K SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 30, 2003 IGENE BIOTECHNOLOGY, INC. (Exact name of registrant as specified in its charter) MARYLAND 0-15888 52-1230461 (State or other jurisdiction (Commission (IRS Employer of incorporati |
|
| August 14, 2003 |
10QSB FILING - BODY OF DOCUMENT - INCLUDING EXHIBIT INDEX 10QSB 1 qsb06302003.txt 10QSB FILING - BODY OF DOCUMENT - INCLUDING EXHIBIT INDEX SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 10549 FORM 10-QSB (Mark One) [x] Quarterly report under Section 13 or 15(D) of the Securities Exchange Act of 1934 For the quarterly period ended June 30, 2003 [ ] Transition report under Section 13 or 15(D) of the Exchange Act For the transition period from to Comm |
|
| July 11, 2003 |
8-K/A 1 igene-8ka070903.htm SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (date of earliest event reported) May 6, 2003 IGENE BIOTECHNOLOGY, INC. (Exact name of registrant as specified in its charter) Maryland (State or other jurisdiction of incorporation) 0-15888 (Commissio |
|
| May 14, 2003 |
Exhibit 10.11 FIRST AMENDMENT TO INDENTURE, SECURITIES, WARRANT AGREEMENT AND WARRANT CERTIFICATES THIS FIRST AMENDMENT TO INDENTURE, SECURITIES, WARRANT AGREEMENT AND WARRANT CERTIFICATES (this "First Amendment") is made as of and shall be effective for all purposes as of the 18th day of March, 2003, by and between Igene Biotechnology, Inc., a Maryland corporation (the "Company"), and American St |
|
| May 14, 2003 |
Exhibit 99(b) CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the IGENE Biotechnology, Inc. (the "Company") Quarterly Report on Form 10-QSB for the period ended March 31, 2003, as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, Edward J. Weisb |
|
| May 14, 2003 |
10QSB BODY OF FILING FOR PERIOD ENDED MARCH 31 2003 10QSB 1 qsb03312003body.txt 10QSB BODY OF FILING FOR PERIOD ENDED MARCH 31 2003 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 10549 FORM 10-QSB (Mark One) [ x ] Quarterly report under Section 13 or 15(D) of the Securities Exchange Act of 1934 For the quarterly period ended March 31, 2003 [ ] Transition report under Section 13 or 15(D) of the Exchange Act For the transition period from to Com |
|
| May 14, 2003 |
Exhibit 99(a) CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the IGENE Biotechnology, Inc. (the "Company") Quarterly Report on Form 10-QSB for the period ended March 31, 2003, as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, Stephen F. Hiu, |
|
| May 13, 2003 |
Exhibit 1 Execution Copy JOINT VENTURE AGREEMENT BETWEEN TATE & LYLE FERMENTATION PRODUCTS LTD. |
|
| May 13, 2003 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (date of earliest event reported) May 6, 2003 IGENE BIOTECHNOLOGY, INC. (Exact name of registrant as specified in its charter) Maryland (State or other jurisdiction of incorporation) 0-15888 (Commission File Number) 52-1230461 (IRS |
|
| April 11, 2003 |
PROXY FOR 2003 SHAREHOLDERS MEETING DEF 14A 1 proxy2003.txt PROXY FOR 2003 SHAREHOLDERS MEETING SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant X Filed by a Party other than the Registrant Check the appropriate box: Preliminary Proxy Statement Confidential, for use of the Commission on |
|
| March 31, 2003 |
Exhibit 99 CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the IGENE Biotechnology, Inc. (the "Company") Annual Report on Form 10-KSB for the period ended December 31, 2002, as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, Stephen F. Hiu, Pr |
|
| March 31, 2003 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-KSB (Mark One) [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the fiscal year ended December 31, 2002 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 0-15888 IGENE Biotechnology, Inc. ( |
|
| March 31, 2003 |
Exhibit 99 CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the IGENE Biotechnology, Inc. (the "Company") Annual on Form 10-KSB for the period ended Decembe r 31, 2002, as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, Edward J. Weisberger, Ch |
|
| March 31, 2003 |
Exhibit 99 CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the IGENE Biotechnology, Inc. (the "Company") Quarterly Report on Form 10-QSB for the period ended September 30, 2002, as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, Stein Ulve, Ch |
|
| March 31, 2003 |
AMENDED QUARTERLY REPORT FOR PERIOD ENDED SEPTEMBER 30, 2002 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 10549 FORM 10-QSB/A (Mark One) [ x ] Quarterly report under Section 13 or 15(D) of the Securities Exchange Act of 1934 For the quarterly period ended September 30, 2002 [ ] Transition report under Section 13 or 15(D) of the Exchange Act For the transition period from to Commission file number 0-15888 IGENE Biotechnology, Inc. (Exact name of Small |
|
| March 31, 2003 |
Exhibit 10.9 CONSULTING AGREEMENT The undersigned parties hereby agree that IGENE Biotechnology, Inc. ("IGENE") shall employ Martin L. Gerson ("Consultant") upon the terms and conditions hereinafter stated to provide consulting services and assistances in the following areas: 1). To secure for Igene a manufacturing partner for the production of AstaXin(R). 2). To coordinate and monitor the startup |
|
| March 31, 2003 |
EXHIBIT 23.a. CONSENT OF INDEPENDENT AUDITORS We hereby consent to the incorporation by reference in the Registration Statements Nos. 333-76616, 333-65013 and 333- 6103 each on Form S-8 and to Registration Statement No. 333- 45218 on Form S-3, and in the Annual Report on Form 10- KSB of Igene Biotechnology, Inc. for the year ended December 31, 2002, of our report dated February 26, 2003, relating |
|
| March 31, 2003 |
Exhibit 99 CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the IGENE Biotechnology, Inc. (the "Company") Quarterly Report on Form 10-QSB for the period ended September 30, 2002, as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, Edward J. Weis |
|
| February 20, 2003 |
EX-99 February 10, 2003 Igene Sells ProBio Nutraceuticals Igene Biotechnology Inc. |
|
| February 20, 2003 |
EX-2 STOCK PURCHASE AND SEVERANCE AGREEMENT THIS AGREEMENT dated as of the 4th day of February, 2003 by and among Fermtech AS, a joint stock company incorporated in the kingdom of Norway ("Fermtech"), Igene Biotechnology, Inc. |
|
| February 20, 2003 |
8-K 1 feb2020038kfinal.txt BODY OF 8K FILING FORM 8-K SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 5, 2003 IGENE BIOTECHNOLOGY, INC. (Exact name of registrant as specified in its charter) MARYLAND 0-15888 52-1230461 (State or other jurisdicti |
|
| February 3, 2003 |
SC 13D/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934* (Amendment No. 5) IGENE Biotechnology, Inc. (Name of Issuer) Common Stock, $0.01 Par Value (Title of Class of Securities) 451695 10 0 (CUSIP Number) Martin Neidell, Esq. Stroock & Stroock & Lavan LLP 180 Maiden Lane New York, New York 10038 (212) 806-5400 (Name, Address and |
|
| November 14, 2002 |
Exhibit 99 CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the IGENE Biotechnology, Inc. (the "Company") Quarterly Report on Form 10-QSB for the period ended September 30, 2002, as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, Stein Ulve, Ch |
|
| November 14, 2002 |
Exhibit 99 CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the IGENE Biotechnology, Inc. (the "Company") Quarterly Report on Form 10-QSB for the period ended September 30, 2002, as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, Edward J. Weis |
|
| November 14, 2002 |
QUARTERLY REPORT FOR PERIOD ENDED SEPTEMBER 30 2002 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 10549 FORM 10-QSB (Mark One) [ x ] Quarterly report under Section 13 or 15(D) of the Securities Exchange Act of 1934 For the quarterly period ended September 30, 2002 [ ] Transition report under Section 13 or 15(D) of the Exchange Act For the transition period from to Commission file number 0-15888 IGENE Biotechnology, Inc. (Exact name of Small B |
|
| November 13, 2002 |
8-K/A 1 nov128ka.txt NOVEMBER 12 2002 8K/A FILING SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 10549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 31, 2001 IGENE BIOTECHNOLOGY, INC. (Exact name of registrant as specified in its charter) MARYLAND 0-15888 52-1230461 State or other Com |
|
| September 17, 2002 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934* (Amendment No. 4) IGENE Biotechnology, Inc. (Name of Issuer) Common Stock, $0.01 Par Value (Title of Class of Securities) 451695 10 0 (CUSIP Number) Martin Neidell, Esq. Stroock & Stroock & Lavan LLP 180 Maiden Lane New York, New York 10038 (212) 806-5400 (Name, Address and Telephone |
|
| September 17, 2002 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ANNUAL STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP FORM 5 [ ] Check box if no longer subject to Section 16. Form 4 or Form 5 obligations may contine. See Instruction 1(b). [ ] Form 3 Holdings Reported [X]Form 4 Transactions Reported OMB APPROVAL OMB NUMBER: 3235-0362 Expires: January 31, 2005 Estimated average burden hours pe |
|
| August 14, 2002 |
10QSB 1 qsb062002.txt QUARTER ENDED JUNE 30 2002 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 10549 FORM 10-QSB (Mark One) [x] Quarterly report under Section 13 or 15(D) of the Securities Exchange Act of 1934 For the quarterly period ended June 30, 2002 [ ] Transition report under Section 13 or 15(D) of the Exchange Act For the transition period from to Commission file number 0-15888 IGENE |
|
| August 14, 2002 |
Exhibit 99 CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the IGENE Biotechnology, Inc. (the "Company") Quarterly Report on Form 10-QSB for the period ended June 30, 2002, as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, Stein Ulve, Chief E |
|
| August 14, 2002 |
Exhibit 99 CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the IGENE Biotechnology, Inc. (the "Company") Quarterly Report on Form 10-QSB for the period ended June 30, 2002, as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, Edward J. Weisberge |
|
| May 31, 2002 |
PROXY FOR 2002 SHAREHOLDERS MEETING SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant X Filed by a Party other than the Registrant Check the appropriate box: Preliminary Proxy Statement Confidential, for use of the Commission only (as permitted by Rule 14a-6(e)(2) X Definitive Proxy Statement Definitive Additional Materials Soliciting Material Under Rule 14a-12 Igene Biotechnology, Inc. |
|
| May 15, 2002 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 10549 FORM 10-QSB (Mark One) [x] Quarterly report under Section 13 or 15(D) of the Securities Exchange Act of 1934 For the quarterly period ended March 31, 2002 [ ] Transition report under Section 13 or 15(D) of the Exchange Act For the transition period from to Commission file number 0-15888 IGENE Biotechnology, Inc. (Exact name of Small Busines |
|
| April 1, 2002 |
EXHIBIT 23.b. CONSENT OF INDEPENDENT AUDITORS We hereby consent to the incorporation by refernce in the Registration Statements Nos. 333-76616, 333-65013 and 333-6103 each on Form S-8 and to Registration Statement No. 333-45218 on Form S-3, and in the Annual Report on Form 10-KSB of Igene Biotechnology, Inc. for the year ended December 31, 2001, of our report dated February 20, 2002 (March 27, 200 |
|
| April 1, 2002 |
EXHIBIT 23.a. CONSENT OF INDEPENDENT AUDITORS We hereby consent to the incorporation by refernce in the Registration Statements Nos. 333-76616, 333-65013 and 333-6103 each on Form S-8 and to Registration Statement No. 333-45218 on Form S-3, and in the Annual Report on Form 10-KSB of Igene Biotechnology, Inc. for the year ended December 31, 2001, of our report dated February 20, 2001 (March 27, 200 |
|
| April 1, 2002 |
10KSB FOR YEAR ENDED DECEMBER 31, 2001 10KSB 1 ksb2001.txt 10KSB FOR YEAR ENDED DECEMBER 31, 2001 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-KSB (Mark One) [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the fiscal year ended December 31, 2001 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to |
|
| March 6, 2002 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 10549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 5, 2002 IGENE BIOTECHNOLOGY, INC. (Exact name of registrant as specified in its charter) MARYLAND 0-15888 52-1230461 (State or other jurisdiction (Commission IRS Employer of incorporation) |
|
| January 11, 2002 |
Exhibit 23.(b) Berenson & Company LLP CERTIFIED PUBLIC ACCOUNTANTS AND CONSULTANTS 135 West 50th Street New York, NY 10020 212 977.6800 FAX: 212 245.3808 212 245.7098 Consent of Independent Auditors We hereby consent to the incorporation by reference in the registration statement on Form S-8 pertaining to the 2001 Stock Incentive Plan of IGENE Biotechnology, Inc., of our report dated February 23, |
|
| January 11, 2002 |
REGISTRATION NO. 333- SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 IGENE BIOTECHNOLOGY, INC. (Exact name of registrant as specified in its charter) MARYLAND 52-1230461 (State or other jurisdiction (IRS employer of incorporation or organization) identification no.) 9110 RED BRANCH ROAD COLUMBIA, MARYLAND 21045 (410) 997-259 |
|
| January 11, 2002 |
Exhibit 3.1(b) IGENE BIOTECHNOLOGY, INC. ARTICLES OF AMENDMENT IGENE Biotechnology, Inc., a Maryland corporation, having its principal office in Columbia, Maryland (the "Corporation"), hereby certifies to the State Department of Assessments and Taxation of Maryland that: FIRST: The charter of the Corporation is hereby amended by striking out Article FIFTH in its entirety and inserting in lieu ther |
|
| January 11, 2002 |
Exhibit 24 POWER OF ATTORNEY Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated. |
|
| January 11, 2002 |
Exhibit 4 IGENE BIOTECHNOLOGY, INC. 2001 STOCK INCENTIVE PLAN 1. PURPOSE. The purpose of the 2001 Stock Incentive Plan (the "Plan") is to further the long term stability and financial success of IGENE Biotechnology, Inc. and its subsidiaries (collectively the "Company") by attracting and retaining employees through the use of stock-based incentives, and to provide employees with an additional ince |
|
| January 4, 2002 |
EXHIBIT 2 STOCK PURCHASE AGREEMENT AGREEMENT dated this 9th day of October, 2001, by and among Fermtech ("Fermtech"), the persons or entities whose names are set forth on Schedule A attached hereto (collectively with Fermtech, the "Stockholders") and Igene Biotechnology, Inc. |
|
| January 4, 2002 |
FORM 8-K SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 21, 2001 IGENE BIOTECHNOLOGY, INC. (Exact name of registrant as specified in its charter) MARYLAND 0-15888 52-1230461 (State or other jurisdiction (Commission (IRS Employer of incorporatio |
|
| January 4, 2002 |
EXHIBIT 99 PRESS RELEASE FOR IMMEDIATE RELEASE Contact: Stephen F. Hiu Igene Biotechnology, Inc. (410) 997-2599 IGENE PURCHASES THEIR EXCLUSIVE SALES AGENT PROBIO Columbia, Maryland, January 3, 2002. Igene Biotechnology, Inc. Columbia, Maryland (OTC:IGNE) announced today that its Board of Directors has concluded a stock purchase agreement of its exclusive sales agent ProBio Nutraceuticals A.S., Tr |
|
| November 13, 2001 |
THIRD QUARTER 2001 FOR IGENE BIOTECHNOLOGY, INC. 10QSB 1 r10q-930.txt THIRD QUARTER 2001 FOR IGENE BIOTECHNOLOGY, INC. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 10549 FORM 10-QSB (Mark One) [ x ] Quarterly report under Section 13 or 15(D) of the Securities Exchange Act of 1934 For the quarterly period ended September 30, 2001 [ ] Transition report under Section 13 or 15(D) of the Exchange Act For the transition period from to Commissio |
|
| September 25, 2001 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934* (Amendment No. 4) IGENE Biotechnology, Inc. (Name of Issuer) Common Stock, $0.01 Par Value (Title of Class of Securities) 451695 10 0 (CUSIP Number) Martin Neidell, Esq. Stroock & Stroock & Lavan LLP 180 Maiden Lane New York, New York 10038 (212) 806-5400 (Name, Address and Telephone |
|
| September 10, 2001 |
4 1 igene-4090601.htm 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP FORM 4 / / Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b) OMB APPROVAL OMB NUMBER: 3235-0287 Expires: December 31, 2001 Estimated average burden hours per response.........0.5 Filed pursuant |
|
| August 14, 2001 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 10549 FORM 10-QSB (Mark One) [x] Quarterly report under Section 13 or 15(D) of the Securities Exchange Act of 1934 For the quarterly period ended June 30, 2001 [ ] Transition report under Section 13 or 15(D) of the Exchange Act For the transition period from to Commission file number 0-15888 IGENE Biotechnology, Inc. (Exact name of Small Business |
|
| June 12, 2001 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported) June 11, 2001 IGENE Biotechnology, Inc. |
|
| May 15, 2001 |
QUARTERLY FOR PERIOD ENDED MARCH 31, 2001 10QSB 1 qsb03312001.txt QUARTERLY FOR PERIOD ENDED MARCH 31, 2001 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 10549 FORM 10-QSB (Mark One) [x] Quarterly report under Section 13 or 15(D) of the Securities Exchange Act of 1934 For the quarterly period ended March 31, 2001 [ ] Transition report under Section 13 or 15(D) of the Exchange Act For the transition period from to Commission file num |
|
| May 4, 2001 |
SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant X Filed by a Party other than the Registrant Check the appropriate box: Preliminary Proxy Statement Confidential, for use of the Commission only (as permitted by Rule 14a-6(e)(2) X Definitive Proxy Statement Definitive Additional Materials Soliciting Material Under Rule 14a-12 Igene Biotechnology, Inc. |
|
| May 4, 2001 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported) April 30, 2001 IGENE Biotechnology, Inc. |
|
| April 20, 2001 |
SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant X Filed by a Party other than the Registrant Check the appropriate box: X Preliminary Proxy Statement Confidential, for use of the Commission only (as permitted by Rule 14a-6(e)(2) Definitive Proxy Statement Definitive Additional Materials Soliciting Material Under Rule 14a-12 Igene Biotechnology, Inc. |
|
| April 2, 2001 |
EXHIBIT 10.8 RED BRANCH CENTER 9110 Red Branch Road Columbia, Maryland FIRST AMENDMENT TO LEASE THIS FIRST AMENDMENT TO LEASE made this 13th day of September, 2000, by and between RED BRANCH CENTER, LLC, successor to Columbia Warehouse Limited Partnership and Glenborough Properties, L.P. (hereinafter "Landlord") and IGENE BIOTECHNOLOGY, INC. (hereinafter "Tenant"). WHEREAS, Tenant and Columbia War |
|
| April 2, 2001 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-KSB (Mark One) [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the fiscal year ended December 31, 2000 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the transition period from to Commission file number 0-15888 IGENE Biotechnology, Inc. |
|
| April 2, 2001 |
EXHIBIT 10.9 [*] Refers to confidential portions of document omitted pursuant to a request for confidential treatment under Rule 406 under the Securities Act of 1933, and filed separately with the Commission. SALES AGENCY AGREEMENT BETWEEN: Igene Biotechnology Inc., 9110 Red Branch Road, Columbia, MD 21045, USA, a Company incorporated under the laws of the State of Maryland (hereinafter referred t |
|
| April 2, 2001 |
EXHIBIT 10.7 [*] Refers to confidential portions of document omitted pursuant to a request for confidential treatment under Rule 406 under the Securities Act of 1933, and filed separately with the Commission. MANUFACTURING AGREEMENT THIS MANUFACTURING AGREEMENT (this "Agreement") is effective as of the 20th day of May 2000 between Igene Biotechnology, Inc. of 9110 Red Branch Road, Columbia, Maryla |
|
| November 14, 2000 |
5 1 9-MOS DEC-31-2000 SEP-30-2000 305,529 0 131,932 0 808,127 1,457,736 312,755 181,360 2,117,243 644,800 9,421,803 415,003 0 622,089 (8,341,652) 2,117,243 129,575 129,575 198,702 415,761 0 0 169,298 (652,186) 0 (652,186) 0 0 0 (652,186) (0.01) (0.01) |
|
| November 14, 2000 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 10549 FORM 10-QSB (Mark One) [x] Quarterly report under Section 13 or 15(D) of the Securities Exchange Act of 1934 For the quarterly period ended September 30, 2000 [ ] Transition report under Section 13 or 15(D) of the Exchange Act For the transition period from to Commission file number 0-15888 IGENE Biotechnology, Inc. (Exact name of Small Bus |
|
| October 5, 2000 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP FORM 4 / / Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b) OMB APPROVAL OMB NUMBER: 3235-0287 Expires: December 31, 2001 Estimated average burden hours per response.........0.5 Filed pursuant to Section 16(a) of the |
|
| October 5, 2000 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934* (Amendment No. 4) IGENE Biotechnology, Inc. (Name of Issuer) Common Stock, $0.01 Par Value (Title of Class of Securities) 451695 10 0 (CUSIP Number) Martin Neidell, Esq. Stroock & Stroock & Lavan LLP 180 Maiden Lane New York, New York 10038 (212) 806-5400 (Name, Address and Telephone N |
|
| September 22, 2000 |
SC 13D/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934* (Amendment No. 3) IGENE Biotechnology, Inc. (Name of Issuer) Common Stock, $0.01 Par Value (Title of Class of Securities) 451695 10 0 (CUSIP Number) Martin Neidell, Esq. Stroock & Stroock & Lavan LLP 180 Maiden Lane New York, New York 10038 (212) 806-5400 (Name, Address and Te |
|
| September 22, 2000 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ANNUAL STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP FORM 5 [ ] Check box if no longer subject to Section 16. Form 4 or Form 5 obligations may contine. See Instruction 1(b). [ ] Form 3 Holdings Reported [X]Form 4 Transactions Reported OMB APPROVAL OMB NUMBER: 3235-0362 Expires: December 31, 2001 Estimated average burden hours p |
|
| September 18, 2000 |
Commission File No. 333-45218 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 10549 FORM S-3/A REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 IGENE Biotechnology, Inc. (Exact name of Small Business Issuer as Specified in its Charter) Maryland 52-1230461 (State or Other Jurisdiction of (IRS Employer Incorporation or organization) Identification No.) 9110 Red Branch Road C |
|
| September 6, 2000 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 10549 FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 IGENE Biotechnology, Inc. (Exact name of Small Business Issuer as Specified in its Charter) Maryland 52-1230461 (State or Other Jurisdiction of (IRS Employer Incorporation or organization) Identification No.) 9110 Red Branch Road Columbia, Maryland 21045-2024 (41 |
|
| August 14, 2000 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 10549 FORM 10-QSB (Mark One) [x] Quarterly report under Section 13 or 15(D) of the Securities Exchange Act of 1934 For the quarterly period ended June 30, 2000 [ ] Transition report under Section 13 or 15(D) of the Exchange Act For the transition period from to Commission file number 0-15888 IGENE Biotechnology, Inc. (Exact name of Small Business |
|
| August 14, 2000 |
5 1 6-MOS DEC-31-2000 JUN-30-2000 100,099 0 96,036 0 627,180 1,027,319 308,373 176,548 1,705,237 294,268 8,957,611 410,768 0 562,089 (8,225,231) 1,705,237 180,631 180,631 185,224 390,507 0 0 169,217 (562,167) 0 (562,167) 0 0 0 (562,167) (0.01) (0.01) |
